Can Chemotherapy and Radiation Cure Esophageal Cancer?

Chemotherapy combined with radiation can cure esophageal cancer, though the chances depend heavily on the stage at diagnosis, the tumor type, and whether surgery is part of the plan. Among patients treated with chemoradiation alone (no surgery), roughly three in ten are alive five years later. When chemoradiation is given before surgical removal of the esophagus, five-year survival climbs higher still. These numbers reflect real progress, but they also make clear that esophageal cancer remains one of the more difficult cancers to beat, and the treatment path is rarely simple.

Chemoradiation Without Surgery

When doctors refer to “definitive chemoradiotherapy,” they mean using chemotherapy and radiation as the primary and complete treatment, with no surgery planned. This approach is used for patients whose tumors sit in a location that makes surgery impractical (such as the cervical esophagus, near the throat), for patients whose overall health makes a major operation too risky, and sometimes because the patient simply prefers to avoid surgery.

A retrospective study of 157 patients treated this way found a median overall survival of about 23 months, with roughly 39% alive at three years and 31% alive at five years.¹ Those numbers varied by the reason for choosing chemoradiation. Patients who had tumors that could not be surgically removed fared worst, with a median survival of about 11 months. Patients who chose chemoradiation by preference, or who were medically unfit for surgery, did better. The fact that about a third of all patients in the study were alive at five years shows that cure is possible without surgery, even if it is not the most common outcome.

Chemoradiation Before Surgery

The most well-established use of chemoradiation in esophageal cancer is as a preoperative (neoadjuvant) treatment, meaning patients receive several weeks of combined chemotherapy and radiation before undergoing esophagectomy. The landmark trial that cemented this approach, known as the CROSS trial, compared chemoradiation followed by surgery against surgery alone. After long-term follow-up, patients who received chemoradiation before surgery had a median overall survival of about 49 months, compared with 24 months for surgery alone.² About 29% of patients who went to surgery after chemoradiation had no detectable cancer left in the removed tissue, a finding called a pathologic complete response.

Extended follow-up of the same trial, with a median observation period of over seven years, confirmed that the survival benefit held up over time.³ This approach is now widely considered a standard of care for patients with locally advanced but resectable esophageal cancer.

Why the Type of Tumor Matters So Much

Esophageal cancer comes in two main forms: squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma tends to arise in the upper and middle portions of the esophagus, while adenocarcinoma usually develops in the lower esophagus near the stomach, often in the setting of long-standing acid reflux. These two tumor types respond to radiation quite differently, and that difference shapes treatment decisions.

In the CROSS trial, the benefit of adding chemoradiation before surgery was dramatic for squamous cell carcinoma: median survival jumped from about 21 months with surgery alone to over 81 months with chemoradiation plus surgery. For adenocarcinoma, the improvement was real but more modest, from about 27 months to 43 months.³ The pathologic complete response rate after chemoradiation was also roughly twice as high in squamous cell carcinoma (49%) as in adenocarcinoma (23%).⁴

This differential sensitivity to radiation has led some experts to argue that adenocarcinoma patients may not benefit as much from radiation-containing regimens and could be exposed to extra toxicity for less payoff.⁵ That question has fueled research into whether chemotherapy alone before surgery might be better for adenocarcinoma.

Chemotherapy Alone vs Chemoradiation Before Surgery for Adenocarcinoma

The ESOPEC trial, published in the New England Journal of Medicine, directly compared two preoperative strategies for esophageal adenocarcinoma: chemotherapy alone (the FLOT regimen, given both before and after surgery) versus chemoradiation followed by surgery (the CROSS protocol). After a median follow-up of 55 months, three-year overall survival was about 57% with perioperative chemotherapy and about 51% with preoperative chemoradiation. Median survival was 66 months in the chemotherapy group versus 37 months in the chemoradiation group.⁶

This result surprised some oncologists, because it suggested that for adenocarcinoma specifically, a more intensive chemotherapy-only approach outperformed a regimen that included radiation. An earlier propensity-matched comparison had found similar three-year survival between the two approaches (about 63% for FLOT and 60% for CROSS), though the pathologic response rate was higher with chemoradiation.⁷ The ESOPEC trial’s larger size and randomized design gives it more weight, and it is shifting practice for esophageal adenocarcinoma toward perioperative chemotherapy in many centers.

For squamous cell carcinoma, preoperative chemoradiation remains the dominant strategy, given how well these tumors respond to radiation.

Does Adding Surgery to Chemoradiation Improve Survival?

This is a question that patients understandably ask: if chemoradiation can shrink or even eliminate the tumor, do you still need such a major operation? Esophagectomy is one of the most complex abdominal surgeries, and it carries real risks.

A Cochrane systematic review examined trials comparing chemoradiation alone to chemoradiation followed by surgery. It found that adding surgery made little or no difference to overall survival. However, surgery did substantially reduce the chance of the cancer coming back locally. The trade-off was a higher risk of treatment-related death with the surgical approach.⁸

This creates a genuine dilemma. Surgery offers better local control, meaning the tumor is less likely to grow back in the original spot. But overall survival ends up similar because some patients who undergo surgery die from surgical complications rather than cancer. Individual fitness, tumor location, and patient preference all play into this decision, and it remains an area where oncology teams weigh the options case by case.

Side Effects and Tolerability

Chemoradiation for esophageal cancer is not easy on the body. The esophagus sits in the chest surrounded by the heart, lungs, and spine, so radiation aimed at an esophageal tumor inevitably hits nearby structures. Common acute side effects include difficulty swallowing (which often gets worse before it gets better), fatigue, nausea, and drops in blood cell counts that increase the risk of infection. In a study of older patients receiving chemoradiation, about 22% experienced severe (grade 3 or higher) toxicity, and about 37% of those on concurrent chemotherapy needed their doses reduced.⁹

Esophageal stricture, a narrowing of the esophagus caused by scarring from radiation, is a well-known delayed complication. One study with 20 years of follow-up data found that strictures developed in about 58% of patients overall, with the rate reaching 76% in those treated with radiation alone (without concurrent chemotherapy).¹⁰ Most of these can be managed with endoscopic dilation (stretching the narrowed area) or stent placement.¹¹

Heart Damage as a Long-Term Risk

For patients who survive esophageal cancer, there is growing awareness that radiation to the chest can leave a lasting mark on the heart. A study of long-term survivors who had received preoperative chemoradiation found signs of radiation-induced scarring (fibrosis) in the heart muscle. The degree of scarring increased proportionally with the radiation dose each part of the heart had received.¹² This finding underscores the importance of minimizing heart exposure during radiation planning, and it is one reason proton beam therapy has attracted interest.

A randomized trial comparing proton beam therapy to conventional intensity-modulated radiation therapy (IMRT) in esophageal cancer found that proton therapy caused significantly less collateral damage to surrounding tissues. The burden of side effects was more than twice as high with IMRT.¹³ Proton beam therapy is not yet available at all cancer centers, but it represents a promising way to reduce the long-term toll of treatment.

Recurrence Patterns After Treatment

Even when chemoradiation and surgery appear to eliminate the cancer, recurrence is a common reality. In a large study of over 1,100 esophageal cancer patients treated with various multimodal approaches, 38% developed a recurrence. Among those who relapsed, about 55% had distant metastases (cancer spreading to other organs), 28% had locoregional recurrence (cancer returning near the original site), and 17% had both.¹⁴

The recurrence pattern differs by tumor type. Squamous cell carcinoma tends to recur locally but is less prone to spreading to distant organs. Adenocarcinoma, by contrast, has a higher rate of distant metastases to the liver, bones, and brain.¹⁵ For patients who achieve a complete response after definitive chemoradiation for proximal esophageal cancer, most recurrences develop within the first three years, which has led to suggestions that intensive surveillance could be shortened after that window.¹⁶

Can You Skip Surgery If the Tumor Disappears?

When chemoradiation produces a clinical complete response, meaning imaging and endoscopy show no remaining tumor, a natural question is whether the patient still needs surgery. The idea of “watch and wait,” actively monitoring the patient with regular imaging and biopsies instead of proceeding to esophagectomy, has gained traction in recent years.

Early results from the preSINO trial suggested that patients with squamous cell carcinoma who achieved a clinical complete response after chemoradiation could delay or avoid surgery through active surveillance, with regular evaluations to catch any signs of residual or recurrent disease.¹⁷ A separate case series examining a watch-and-wait approach after chemoimmunotherapy (chemotherapy plus an immune checkpoint inhibitor) found that over an average follow-up of about two and a half years, no deaths or distant metastases occurred. Patients who experienced local recurrence were offered salvage surgery.¹⁸

This approach is still considered investigational. The challenge lies in accurately determining whether the cancer is truly gone. PET scans are commonly used to assess response, and combining PET findings with clinical staging can improve prediction of pathologic complete response.¹⁹ However, PET scans are not perfect: one study found that qualitative PET assessment missed residual disease in about 15% of patients.²⁰ Researchers are also exploring molecular biomarkers, including gene signatures, that could predict which patients will respond well to chemoradiation and might be candidates for organ preservation. One study identified a three-gene signature that predicted response to the CROSS regimen with high accuracy.²¹

When Cure Is Not the Goal

For patients with advanced esophageal cancer that cannot be cured, chemoradiation still plays an important palliative role, particularly for relieving dysphagia (difficulty swallowing). Being unable to eat or drink comfortably is one of the most distressing symptoms of esophageal cancer, and chemoradiation can meaningfully restore swallowing function.

One study found that about 60% of patients with advanced-stage disease had improvement in their swallowing after palliative chemoradiation, and the median duration of that improvement was about seven and a half months.²² Another found that nearly half of patients treated for palliation reached a point where they could swallow normally again.²³ A phase I trial of a shorter, hypofractionated chemoradiation schedule found improvement in swallowing beginning within a few weeks, with a median dysphagia-free survival of about six months and overall survival of about nine months.²⁴

Adding Immunotherapy to the Mix

Immune checkpoint inhibitors have reshaped treatment for several cancers, and esophageal cancer is no exception. These drugs work by helping the immune system recognize and attack cancer cells. In esophageal cancer, immunotherapy is being tested both alongside chemoradiation and after it.

An analysis of the National Cancer Database found that giving immunotherapy after neoadjuvant chemoradiation and surgery (adjuvant immunotherapy) was associated with significantly improved survival compared to no immunotherapy. Interestingly, giving immunotherapy before surgery (neoadjuvant immunotherapy) did not show the same benefit in that dataset.²⁵ This is an area of active investigation, and the addition of immunotherapy has the potential to push cure rates higher, though it comes with its own side effects, including immune-related complications like thyroid problems, rash, and inflammation.

Nutrition Support During Treatment

One underappreciated factor in esophageal cancer treatment is nutrition. The disease itself makes eating difficult, and chemoradiation often makes swallowing temporarily worse. Severe weight loss during treatment can force dose reductions in chemotherapy, delay radiation schedules, and increase infection risk, all of which can compromise the treatment’s cancer-fighting ability.

A randomized trial of patients receiving chemoradiation for esophageal cancer found that those who received structured enteral nutrition support (tube feeding) lost far less weight during treatment than those who did not: less than one kilogram on average versus about three and a half kilograms. The supported group also had lower rates of severe drops in white blood cell counts and fewer infections. Perhaps most importantly, 97% of the nutrition-supported group completed their full chemoradiation course compared with 88% of the control group.²⁶ Completing the full planned course of treatment matters because interruptions and dose reductions can reduce the chance of cure.

Consolidation Chemotherapy After Chemoradiation

For patients with squamous cell carcinoma treated with definitive chemoradiation (no surgery), one emerging question is whether giving additional rounds of chemotherapy after chemoradiation finishes, known as consolidation chemotherapy, can prevent the cancer from spreading. A population-based study found that consolidation chemotherapy was associated with fewer distant metastases. Among patients who received it, about 22% developed distant spread, compared with about 44% in those who did not.²⁷ A separate retrospective analysis reached a similar conclusion, finding significantly fewer distant metastases in the consolidation group, though local recurrence rates were not significantly different between the groups.²⁸ This strategy is not yet standard practice, but the findings suggest it could help address the significant problem of distant relapse in patients managed without surgery.